Novo Nordisk Shares Tumble After 2030 Growth Targets Signal Slowdown

Novo Nordisk's shares fell by as much as 6% on Monday after the Danish pharmaceutical giant outlined long-term strategic targets that signaled a moderation of its explosive growth. The new ambitions were presented to investors during a capital markets day held in London.

Growth Outlook Disappoints Market

The primary driver of the negative market reaction was the company's forecast for the 2026 to 2030 period. Novo Nordisk said it expects compound annual revenue growth to be “in line with industry peers,” a projection that appeared to temper expectations for the continued outperformance that has propelled its valuation.

The company also stated it aims to keep its operating margin broadly stable during that timeframe. This guidance suggests a shift from a phase of hyper-growth, driven by its blockbuster GLP-1 drugs, to a more normalized trajectory comparable to other major pharmaceutical firms like Eli Lilly, Roche, and Pfizer, which it listed as peers.

Strategic Ambitions to 2030

Ad

Despite the market's reaction to the top-line growth forecast, Novo Nordisk detailed several ambitious operational and pipeline goals. The company clarified these targets are based on a 2026 baseline and do not constitute formal financial guidance.

Key targets announced by the company include:

• Generating more than DKK 150 billion in sales by 2035 from its risk-adjusted pipeline.
• Launching more than five drugs with potential for blockbuster sales by 2030.
• Expanding capacity to provide oral GLP-1 treatments to over 60 million patients globally by 2030.
• Advancing at least five Phase 3 programs in obesity and diabetes, and at least five in other therapeutic areas.
• Maintaining what it described as an attractive dividend per share for investors.